Loading
companiesCompany
Lucence
Lucence offers blood tests that read both tumour DNA and tumour RNA from a single sample to help doctors choose targeted treatments, and is developing a multi-cancer screening test.
Overview
Lucence is a precision diagnostics company with laboratories in Singapore and Palo Alto, California, and an office in Hong Kong. Its AmpliMARK amplicon-based technology enables ultrasensitive detection of cell-free DNA and RNA. The flagship LiquidHALLMARK assay profiles circulating tumour DNA and RNA in one blood draw to identify actionable mutations and fusions in solid tumours, with a cerebrospinal fluid version for central nervous system cancers. LucenceINSIGHT is a multi-cancer early detection (MCED) test the company states screens at 99 percent specificity, and LucenceMONITOR addresses treatment monitoring. Laboratories are CAP-accredited and CLIA-certified. Data on combined ctDNA and ctRNA yield were presented at ASCO 2025, and in March 2026 Lucence, DxD Hub and the National Cancer Centre Singapore launched an S$6 million research collaboration.
Notes
top- No funding round could be sourced from primary releases on the company site; stage set to startup provisionally. Founding year not sourced. Cancer and target tags reflect typical LiquidHALLMARK coverage described generically on the site rather than a fetched panel list.
Similar pages
- CompanyImagene AI
- Key paperNILE: clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer
- CompanyInivata
Shares ALK, EGFR, KRAS, Comprehensive genomic profiling.
- Key paperClinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer
- PersonTakashi Kohno
Shares RET, RNA sequencing & expression profiling, Comprehensive genomic profiling, Non-small-cell lung cancer.
- InstitutionAichi Cancer Center
Shares ALK, EGFR, Comprehensive genomic profiling, HR-positive / HER2-negative breast cancer.
- CollectionLUNGevity Foundation (and GO2 for Lung Cancer)
Shares ALK, EGFR, KRAS, Comprehensive genomic profiling.
- Key paperProspective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies